Back to results
US 2025/0019439 A1Published application
Anti-idiotype antibodies
AssigneeAdimab, LLC
InventorWilliam George ROACH
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to anti-idiotypic antibodies binding to anti-CD3 antibodies, and uses thereof, e.g., in assays and methods of treatment.
Claims47
An antibody or antigen-binding fragment thereof comprising:
- (A) a heavy chain variable domain (VH) polypeptide comprising a set of VH complementarity determining regions:
- VH (CDR)1 (CDRH1), VH CDR2 (CDRH2), and VH CDR3 (CDRH3);
- and
- (B) a light chain variable domain (VL) polypeptide comprising a set of VL complementarity determining regions:
- VL CDR1 (CDRL1), VL CDR2 (CDRL2), and VL CDR3 (CDRL3),
- wherein at least three, four, five or all six of said CDRs comprises:
- (i) the amino acid sequence of a corresponding VH or VL CDR contained in any of the variable domain sequences listed in Table 3A or 3B;
- and/or
- (ii) the amino acid sequence of a corresponding VH or VL CDR selected from any of the VH or VL CDRs listed in Table 4A or 4B,
- optionally wherein:
- (A) the VH polypeptide comprises a set of VH CDRs:
- CDRH1, CDRH2, and CDRH3 of a specific antibody selected from those listed in Table 4A;
- and/or
- (B) the VL polypeptide comprises a set of VL CDRs:
- CDRL1, CDRL2, and CDRL3 of a specific antibody selected from those listed in Table 4B.
12 more elements
An antibody or antigen-binding fragment thereof comprising:
- (A) a VH polypeptide comprising:
- (a) a CDRH1 comprising the amino acid sequence of:
- (i) the CDRH1 contained in any one of ADI-34134, ADI-34145, ADI-30242, ADI-34131, ADI-34132, ADI-34133, ADI-34135, ADI-34136, ADI-34137, ADI-34138, ADI-30254, ADI-34139, ADI-34140, ADI-34141, ADI-34142, ADI-34143, ADI-34144, and ADI-34146;
- (ii) the CDRH1 contained in any one of SEQ ID NOS:
- 640, 880, 560, 580, 600, 620, 660, 680, 700, 720, 740, 760, 780, 800, 820, 840, 860, and 900;
- and/or
- (iii) any one of SEQ ID NOS:
- 642, 882, 562, 582, 602, 622, 662, 682, 702, 722, 742, 762, 782, 802, 822, 842, 862, 902, 922, and 942;
- (b) a CDRH2 comprising the amino acid sequence of:
- (i) the CDRH2 contained in any one of ADI-34134, ADI-34145, ADI-30242, ADI-34131, ADI-34132, ADI-34133, ADI-34135, ADI-34136, ADI-34137, ADI-34138, ADI-30254, ADI-34139, ADI-34140, ADI-34141, ADI-34142, ADI-34143, ADI-34144, and ADI-34146;
- (ii) the CDRH2 contained in any one of SEQ ID NOS:
- 640, 880, 560, 580, 600, 620, 660, 680, 700, 720, 740, 760, 780, 800, 820, 840, 860, and 900;
- and/or
- (iii) any one of SEQ ID NOS:
- 644, 884, 564, 584, 604, 624, 664, 684, 704, 724, 744, 764, 784, 804, 824, 844, 864, 904, 924, and 944;
- and/or
- (c) a CDRH3 comprising the amino acid sequence of:
- (i) the CDRH3 contained in any one of ADI-34134, ADI-34145, ADI-30242, ADI-34131, ADI-34132, ADI-34133, ADI-34135, ADI-34136, ADI-34137, ADI-34138, ADI-30254, ADI-34139, ADI-34140, ADI-34141, ADI-34142, ADI-34143, ADI-34144, and ADI-34146;
- (ii) the CDRH3 contained in any one of SEQ ID NOS:
- 640, 880, 560, 580, 600, 620, 660, 680, 700, 720, 740, 760, 780, 800, 820, 840, 860, and 900;
- and/or
- (iii) any one of SEQ ID NOS:
- 646, 886, 566, 586, 606, 626, 666, 686, 706, 726, 926, 746, 766, 786, 806, 826, 846, 866, 906, and 946;
- and/or
- (B) a VL polypeptide comprising:
- (a) a CDRL1 comprising the amino acid sequence of:
- (i) the CDRL1 contained in any one of ADI-34134, ADI-34145, ADI-30242, ADI-34131, ADI-34132, ADI-34133, ADI-34135, ADI-34136, ADI-34137, ADI-34138, ADI-30254, ADI-34139, ADI-34140, ADI-34141, ADI-34142, ADI-34143, ADI-34144, and ADI-34146;
- (ii) the CDRL1 contained in any one of SEQ ID NOS:
- 650, 890, 570, 590, 610, 630, 670, 690, 710, 730, 750, 770, 790, 810, 830, 850, 870, and 910;
- (iii) (iii-1) RASQSX1SSX2YLX3 (SEQ ID NO:
- 932), wherein X1 is V or I, X2 is D, S, or deletion (no amino acid), and X3 is A or N, or (iii-2) RSSQSLLX1SNGYNYLD (SEQ ID NO:
- 952), wherein X1=H or Y;
- and/or
- (iv) any one of SEQ ID NOS:
- 652, 892, 572, 592, 612, 632, 672, 692, 712, 732, 752, 772, 792, 812, 832, 852, 872, and 912;
- (b) a CDRL2 comprising the amino acid sequence of:
- (i) the CDRL2 contained in any one of ADI-34134, ADI-34145, ADI-30242, ADI-34131, ADI-34132, ADI-34133, ADI-34135, ADI-34136, ADI-34137, ADI-34138, ADI-30254, ADI-34139, ADI-34140, ADI-34141, ADI-34142, ADI-34143, ADI-34144, and ADI-34146;
- (ii) the CDRL2 contained in any one of SEQ ID NOS:
- 650, 890, 570, 590, 610, 630, 670, 690, 710, 730, 750, 770, 790, 810, 830, 850, 870, and 910;
- (iii) X1ASX2X3X4X5 (SEQ ID NO:
- 934), wherein X1 is G or A, X2 is S or N, X3 is R or L, X4 is A or Q, and X5 is T or S;
- and/or
- (iv) any one of SEQ ID NOS:
- 654, 894, 574, 594, 614, 634, 674, 694, 714, 734, 754, 774, 794, 814, 834, 854, 874, 914, and 954;
- (c) a CDRL3 comprising the amino acid sequence of:
- (i) the CDRL3 contained in any one of ADI-34134, ADI-34145, ADI-30242, ADI-34131, ADI-34132, ADI-34133, ADI-34135, ADI-34136, ADI-34137, ADI-34138, ADI-30254, ADI-34139, ADI-34140, ADI-34141, ADI-34142, ADI-34143, ADI-34144, and ADI-34146;
- (ii) the CDRL3 contained in any one of SEQ ID NOS:
- 650, 890, 570, 590, 610, 630, 670, 690, 710, 730, 750, 770, 790, 810, 830, 850, 870, and 910;
- (iii) (iii-1) X1QX2X3X4X5X6X7T (SEQ ID NO:
- 936), wherein X1 is Q or L, X2 is F, T, or A, X3 is G, L, or H, X4 is R, S, H, P, or T, X5 is V, D, S, T, Y, F, or A, X6 is P or L, and X7 is deletion (no amino acid), I, or W, or (iii-2) MQVX1X2X3PWT (SEQ ID NO:
- 956), wherein X1 is L, R, K, or S, X2 is E, Q, D, or G, and X3 is L, T, or I;
- and/or
- (iv) any one of SEQ ID NOS:
- 656, 896, 576, 596, 616, 636, 676, 696, 716, 736, 756, 776, 796, 816, 836, 856, 876, and 916,
- or an antibody or antigen-binding fragment thereof which comprises a combination of one or more of the foregoing CDRs.
52 more elements
Dependencies are inferred from the claim text.